Association of depth of target lesion response to brigatinib with outcomes in patients with ALK inhibitor-naive ALK plus NSCLC in ALTA-1L
Authors
Camidge, D. R.Kim, H. R.
Ahn, M. J.
Yang, J. C.
Han, J. Y.
Hochmair, M.
Lee, K. H.
Delmonte, A.
Campelo, R. G.
Kim, D. W.
Griesinger, F.
Felip, E.
Califano, Raffaele
Spira, A. I.
Thomas, M.
Gettinger, S. N.
Tiseo, M.
Liu, Y. Y.
Zhang, P. K.
Popat, S.
Affiliation
University of Colorado Cancer Center, Aurora, COIssue Date
2022
Metadata
Show full item recordCitation
Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Hochmair M, et al. Association of depth of target lesion response to brigatinib with outcomes in patients with ALK inhibitor-naive ALK plus NSCLC in ALTA-1L. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680302258.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2022.40.16_suppl.9072Additional Links
https://dx.doi.org/10.1200/JCO.2022.40.16_suppl.9072Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2022.40.16_suppl.9072